Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential gemcitabine-carboplatin and paclitaxel-carboplatin versus carboplatin-paclitaxel in platinum-sensitive recurrent ovarian-related cancers
2004-000722-69Phase 2Active
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
- Start
- Sep 2004
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) comparing Sequential Gemzar + Paraplatin then Taxol + Paraplatin with Paraplatin + Taxol (2 arms). Primary endpoint: Clinical response rate. Started Sep 2004; status: active.
02
Drugs
gemcitabinecarboplatinpaclitaxel
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2004-000722-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000722-69.